propranolol has been researched along with Pancreatic Neoplasms in 17 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe a 72-year-old lady who initially presented with episodic hypoglycemia secondary to an insulinoma that was controlled by diazoxide." | 3.69 | Relapse of medically treated insulinoma following the development of thyrotoxicosis: an assessment of potential mechanisms. ( Alberti, KG; Kendall-Taylor, P; Trajano, LR; Walker, M, 1994) |
| "In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclinical testing." | 1.51 | Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. ( Adile, AA; Bakhshinyan, D; Berger-Becvar, A; de Araujo, ED; Deininger, MW; Fishel, ML; Gawel, JM; Geletu, M; Grimard, ML; Gunning, PT; Heaton, WL; Konieczny, SF; Luchman, HA; O'Hare, T; Raouf, YS; Shah, F; Shouksmith, AE; Singh, SK; Venugopal, C; Weiss, S, 2019) |
| "Using two pancreatic cancer cell lines and immortalized pancreatic duct epithelia in vitro, our current data show that all three cell lines synthesized and released the catecholamine neurotransmitters noradrenaline and adrenaline upon exposure to nicotine and that this activity was regulated by α3, α5, and α7-nAChRs." | 1.38 | Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors α3, α5, and α7. ( Al-Wadei, HA; Al-Wadei, MH; Schuller, HM, 2012) |
| "Propranolol inhibited pancreatic cancer cell proliferation by blocking signaling through the beta-adrenoceptor." | 1.35 | Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. ( Hu, H; Ma, Q; Shen, S; Zhang, D, 2009) |
| "The human pancreatic cancer cell lines, Miapaca-2 and Bxpc-3, were selected for this study, and in both cell lines, beta1-AR and beta2-AR expression was determined by RT-PCR and Western blotting." | 1.35 | Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. ( Guo, K; Hu, H; Li, J; Ma, Q; Wang, L; Zhang, D; Zhang, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (47.06) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, XL | 1 |
| Yang, YR | 1 |
| Mo, XF | 1 |
| Wei, JL | 1 |
| Zhang, XJ | 1 |
| You, QD | 1 |
| Shouksmith, AE | 1 |
| Shah, F | 1 |
| Grimard, ML | 1 |
| Gawel, JM | 1 |
| Raouf, YS | 1 |
| Geletu, M | 1 |
| Berger-Becvar, A | 1 |
| de Araujo, ED | 1 |
| Luchman, HA | 1 |
| Heaton, WL | 1 |
| Bakhshinyan, D | 1 |
| Adile, AA | 1 |
| Venugopal, C | 1 |
| O'Hare, T | 1 |
| Deininger, MW | 1 |
| Singh, SK | 1 |
| Konieczny, SF | 1 |
| Weiss, S | 1 |
| Fishel, ML | 1 |
| Gunning, PT | 1 |
| Zhang, D | 2 |
| Ma, Q | 2 |
| Shen, S | 1 |
| Hu, H | 2 |
| Al-Wadei, HA | 2 |
| Al-Wadei, MH | 2 |
| Schuller, HM | 2 |
| Guo, K | 1 |
| Wang, L | 1 |
| Li, J | 1 |
| Zhang, M | 1 |
| Pham, H | 1 |
| Chen, M | 1 |
| Takahashi, H | 1 |
| King, J | 1 |
| Reber, HA | 1 |
| Hines, OJ | 1 |
| Pandol, S | 1 |
| Eibl, G | 1 |
| Yoshino, G | 1 |
| Kazumi, T | 1 |
| Morita, S | 1 |
| Kobayashi, N | 1 |
| Terashi, K | 1 |
| Baba, S | 1 |
| Blum, I | 3 |
| Rusecki, Y | 1 |
| Doron, M | 3 |
| Lahav, M | 1 |
| Laron, Z | 3 |
| Atsmon, A | 2 |
| Luk'ianchikov, VS | 1 |
| Walker, M | 1 |
| Trajano, LR | 1 |
| Alberti, KG | 1 |
| Kendall-Taylor, P | 1 |
| Russell, ST | 1 |
| Hirai, K | 1 |
| Tisdale, MJ | 1 |
| Eisner, M | 1 |
| Spychalska-Szymańska, T | 1 |
| Stachowski, A | 1 |
| Shaklai, M | 1 |
| Aderka, D | 2 |
| Asherov, J | 1 |
| Pinkhas, J | 1 |
| Imanaka, S | 1 |
| Matsuda, S | 1 |
| Ito, K | 1 |
| Matsuoka, T | 1 |
| Okada, Y | 1 |
| Appleyard, WJ | 1 |
| Lloyd, J | 1 |
17 other studies available for propranolol and Pancreatic Neoplasms
| Article | Year |
|---|---|
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Proliferation; Dose-Response Relationship, Drug; D | 2017 |
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Disease | 2019 |
Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2009 |
Prevention of pancreatic cancer by the beta-blocker propranolol.
Topics: Adrenergic beta-Antagonists; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anticarcinogenic Agen | 2009 |
Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol.
Topics: Adrenergic beta-Antagonists; Blotting, Western; Cell Line, Tumor; Cell Movement; Enzyme-Linked Immun | 2009 |
Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors α3, α5, and α7.
Topics: Adrenergic beta-Agonists; Autocrine Communication; Cell Proliferation; Epinephrine; Epithelial Cells | 2012 |
Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apigenin; Carcinogens; Cell Line, Tumor; Cell Movement; Cell Proliferation; E | 2012 |
Effect of propranolol on glucose-induced insulin response in rats with insulinomas.
Topics: Adenoma, Islet Cell; Animals; Blood Glucose; Glucose; Glucose Tolerance Test; Insulin; Niacinamide; | 1980 |
Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases.
Topics: Adenoma, Islet Cell; Aged; Blood Glucose; Female; Glucagon; Glucose Tolerance Test; Humans; Insulin; | 1983 |
[Diagnosis and treatment of hypoglycemia syndrome].
Topics: Biguanides; Blood Glucose; Diagnosis, Differential; Diet; Glucose Tolerance Test; Humans; Hypoglycem | 1982 |
Relapse of medically treated insulinoma following the development of thyrotoxicosis: an assessment of potential mechanisms.
Topics: Aged; C-Peptide; Diazoxide; Female; Humans; Hypoglycemia; Insulin; Insulin Resistance; Insulinoma; P | 1994 |
Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor.
Topics: Adenylyl Cyclases; Adipocytes; Animals; Appetite Depressants; CHO Cells; Cricetinae; Cyclic AMP; Epi | 2002 |
[Treatment of organic hyperinsulinism with propranolol in the course of insulinoma].
Topics: Adenoma, Islet Cell; Aged; Female; Humans; Hyperinsulinism; Pancreatic Neoplasms; Propranolol | 1977 |
Suppression of hypoglycemic attacks and insulin release by propranolol in a patient with metastatic malignant insulinoma.
Topics: Adenoma, Islet Cell; Female; Humans; Hypoglycemia; Insulin; Insulin Secretion; Middle Aged; Neoplasm | 1977 |
Suppression of hypoglycemia by DL-propranolol in malignant insulinoma.
Topics: Adenoma, Islet Cell; Humans; Hypoglycemia; Pancreatic Neoplasms; Propranolol | 1978 |
Medical treatment for inoperable insulinoma: clinical usefulness of diphenylhydantoin and diltiazem.
Topics: Adenoma, Islet Cell; Aged; Benzazepines; Blood Glucose; C-Peptide; Celiac Artery; Diltiazem; Female; | 1986 |
Pluriglandular syndrome with hyperinsulinism. Cardiomegaly as a possible complication of diazoxide therapy.
Topics: Blood Glucose; Blood Pressure; Cardiomegaly; Child; Diazoxide; Female; Hirsutism; Humans; Hypercalce | 1968 |